Channel Therapeutics Corporation Common Stock (CHRO)
1.0100
-0.0600 (-5.61%)
NYSE · Last Trade: May 14th, 2:05 PM EDT
Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and chronic indications.
Via Benzinga · May 14, 2025
Via Benzinga · April 17, 2025
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via Stocktwits · April 17, 2025
Via Benzinga · April 17, 2025
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via Benzinga · April 17, 2025

Via Benzinga · January 23, 2025

Via Benzinga · November 26, 2024

Via Benzinga · October 18, 2024

Via Benzinga · October 18, 2024

Via Benzinga · October 16, 2024

Via Benzinga · October 4, 2024

Via Benzinga · October 4, 2024

Via Benzinga · October 1, 2024

Via Benzinga · September 26, 2024

Chromocell Therapeutics just reported results for the second quarter of 2024.
Via InvestorPlace · August 20, 2024

Via Benzinga · May 29, 2024

Chromocell Therapeutics just reported results for the first quarter of 2024.
Via InvestorPlace · May 20, 2024

Via Benzinga · April 19, 2024

Via Benzinga · April 19, 2024

Via Benzinga · April 17, 2024

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
Via Benzinga · April 17, 2024